Galmed Pharmaceuticals 주식 (NASDAQ: GLMD)

에 대한 최신 뉴스 Galmed Pharmaceuticals (NASDAQ:GLMD) 주식

Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.

Exclusives

Trading Ideas

AAPL

AMZN

DRUG

GLMD

GNPX

INTC

LUNR

MSFT

MSTR

NVDA

OKLO

PLTR

SMCI

SOFI

TSLA

TVGN

WHLR

WULF

매 거래일마다 수백 개의 헤드라인과 보도자료가 벤징가 프로에 올라와, 트레이더들이 전체 시장과 개별 종목에 대한 최신 뉴스를 확인할 수 있는 소스이다. 2024년 10월에 벤징가 프로에서 가장 많이 검색된 주식들을 살펴보겠다. 현재 가격과 연초 대비 실적은 11월 1일 기준이며 배당금은 포함되지 않았다.

독점: 벤징가 프로에서 10월 가장 많이 검색된 상위 20개 티커 - 테슬라, 엔비디아, DJT 순위는?

Nvidia,Logo,On,Mobile,Phone,Screen,Company,Shares,Rise,Or

APLD

CNEY

GOVX

IMRX

LUMN

NDRA

SMMT

TNON

매일 거래일마다 벤징가 프로(Benzinga Pro)에서 수백 개의 헤드라인과 보도자료가 올라온다. 이는 트레이더들이 전체 시장 및 개별 종목에 대한 최신 뉴스를 확인할 수 있는 소스이다. 2024년 9월에 Benzinga Pro에서 가장 많이 검색된 주식들을 살펴보겠다. 현재 가격과 연초 대비 성과는 9월 30일 기준이며 배당금은 포함되지 않았다.

독점: 9월 벤징가 프로에서 가장 많이 검색된 상위 20개 티커 - 테슬라, 엔비디아, 애플은 어디에?

Stock_Whisper_Index_Logo_6-copy

GOLD

매주 ‘벤징가의 스톡 위스퍼 지수(Benzinga&#39;s Stock Whisper Index)&#39;는 독점 데이터(proprietary data)와 패턴 인식의 조합을 사용하여 표면 바로 아래에서 주목을 끌고 있는 주식 5종목을 소개한다.

벤징가의 &#39;스톡 위스퍼&#39; 지수: 투자자들이 몰래 주시하지만 아직 말하지 않는 주식 5종목

Galmed Pharmaceuticals Ltd. - Ordinary Shares

Galmed Pharmaceuticals Ltd

<ul>
<li>Galmed Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLMD#NASDAQ">GLMD</a>) enters into a Sponsored Project Agreement with Virginia Commonwealth University (VCU) to evaluate Aramchol's effect on overcoming drug resistance in gastrointestinal (GI) cancers. &nbsp;</li>
<li>Aramchol, a first-in-class SCD1 inhibitor, will be studied in combination with standard therapies for advanced colorectal and liver cancers, aiming to reverse treatment resistance and improve outcomes in these high-mortality cancers. &nbsp;</li>
<li>Collaboration builds on breakthrough findings published in Nature Communications <a href="https://doi.org/10.1038/s41467-023-41852-z">(https://doi.org/10.1038/s41467-023-41852-z</a>) linking lipid metabolism to cancer drug resistance, supporting Aramchol's novel mechanism as a promising, synergistic approach.</li>
<li>This initiative is part of a strategic expansion of Galmed's pipeline beyond liver disease into oncology, targeting a large market potential with significant unmet need and reinforcing Galmed's focus on cost-effective, innovative therapies.</li>
</ul>

Biotech

News

Contracts

General

Galmed Pharmaceuticals  Enters Sponsored Project Agreement With Virginia Commonwealth University To Evaluate Aramchol's Effect On Overcoming Drug Resistance In Gastrointestinal Cancers

<ul>
<li>Analysis of blood samples from patients treated with&nbsp;Aramchol in ARMOR (Ph3 MASH Study) provides new and important insights into the biochemical and physiological effects of the drug.</li>
<li>The pharmacodynamic signature associated with Aramchol treatment revealed a decrease in markers of chronic systemic inflammation, oxidative and cardiac stress, and atherosclerotic plaque pathogenesis.
<ul>
<li>Data also show a significant decrease in ANP (Atrial Natriuretic Peptide), a clinically validated marker for heart failure. &nbsp;</li>
</ul>
</li>
</ul>

Galmed Unveils Pharmacodynamic Blood Markers For Aramchol

– AM-001 Study represents a pivotal milestone in Galmed's transition to Aramchol Meglumine, an improved formulation of its lead compound in advanced clinical development &nbsp;– Aramchol Meglumine, a New Chemical Entity (NCE) protected by patents until 2035, is being developed both as a standalone agent and in novel drug combinations for multiple indications influenced by fatty acid metabolism &nbsp;– Initial findings suggest that the new Aramchol Meglumine formulation offers higher bioavailability than Aramchol free acid and that a once-daily, oral 200 mg dose is likely to be optimal for future trials, supporting improved patient compliance and potentially lowering manufacturing costs
TEL AVIV, Israel, April 10, 2025 /PRNewswire/ --&nbsp;Galmed Pharmaceuticals Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLMD#NASDAQ">GLMD</a>) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic, and gastrointestinal oncology indications, today announced positive preliminary results from Part 1 of the Ph1 Bioavailability AM-001 Study of Aramchol Meglumine.
Galmed has successfully advanced Aramchol acid through six clinical trials (up to Ph3) enrolling 661 subjects, establishing both its overall safety and its efficacy in treating NASH (MASH). The N-methylglucamine (meglumine) salt of Aramchol exhibits notable advantages over Aramchol acid, including enhanced solubility, absorption, and systemic exposure, translating to higher bioavailability. In recognition of these benefits, Aramchol Meglumine received NCE patent protection extending until 2035.
Previously, the FDA approved the transition from Aramchol acid to Aramchol Meglumine under a new IND, leveraging cross-reference to the substantial preclinical and clinical data amassed in recent years for Aramchol. The only requirement for this transition was a bioavailability study to compare the two formulations.
The AM-001 study was conducted in response to that FDA request and is also designed to help identify the doses best suited for advancing Aramchol Meglumine into Phase 2 studies. It consists of two parts, comparing single doses of Aramchol acid and Aramchol Meglumine in healthy volunteers. Part 2 of the study is anticipated to conclude in the second half of 2025.
In Part 1 of AM-001, preliminary results demonstrate that a 400 mg dose of Aramchol Meglumine suspension achieved an area under the curve (AUC) nearly double that of Aramchol acid tablets. Based on these outcomes, 200 mg once daily appears to be the optimal dose for subsequent clinical trials. This once-daily regimen not only simplifies patient adherence (moving from twice-daily to once-daily) but is also expected to reduce the overall cost of goods.
"Aramchol is the most advanced down regulator of SCD-1 (Stearoyl – CoA desaturase) in clinical development. Inhibition of SCD-1 has been recently investigated in multiple indications, re-emphasizing its metabolic master switch potential and importance in multiple organs and functions. We expect that the long patent runway of Aramchol Meglumine will allow us to develop the full therapeutical potential of the drug in the planned expansion in cardiometabolic diseases and gastrointestinal cancers we recently announced," said Allen Baharaff, President and CEO of Galmed Pharmaceuticals.

Galmed Announces Part 1 Results From AM-001 Study Of Aramchol Meglumine, An Enhanced Formulation Of The Most Clinically Advanced SCD1 Inhibitor

Maxim Group analyst Naz Rahman downgrades Galmed Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLMD#NASDAQ">GLMD</a>) from Buy to Hold.

Downgrades

Analyst Ratings

Maxim Group Downgrades Galmed Pharmaceuticals to Hold

TEL AVIV, Israel, April 2, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLMD#NASDAQ">GLMD</a>) ('Galmed' or the 'Company'), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic diseases and GI oncological indications, today announced that it has filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2024, with the U.S. Securities and Exchange Commission (the 'SEC').
 &nbsp;

Galmed Pharmaceuticals Files Annual Report On Form 20-F For Fiscal Year Ended December 31, 2024

Galmed Pharmaceuticals Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLMD#NASDAQ">GLMD</a>) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic diseases and GI oncological indications, today announced the grant of a new patent related to its lead compound, Aramchol. The patent covers the use of a combination therapy of Aramchol and Resmetirom (MGL-3196, Rezdiffra) for the treatment of non-alcoholic steatohepatitis (NASH), also known as metabolic dysfunction-associated steatohepatitis (MASH), and liver fibrosis.

Global

Galmed Pharmaceuticals Announces The Grant Of A New Patent Related To Aramchol; Patent Covers The Use Of A Combination Therapy Of Aramchol And Resmetirom For The Treatment Of Non-Alcoholic Steatohepatitis, Also Known As Metabolic Dysfunction-Associated Steatohepatitis, And Liver Fibrosis

Galmed Pharmaceuticals Shares Resumed Trade

Galmed Pharmaceuticals Shares Halted On Circuit Breaker To The Upside, Stock Now Up 67.9%

<a href="https://ppubs.uspto.gov/dirsearch-public/print/downloadBasicPdf/12239712?requestToken=eyJzdWIiOiI3OTM4NzBkYy02ZTJiLTRlNzQtOWFmMC01ZjViMmQyYjMyYTkiLCJ2ZXIiOiIzNTEwMDc4OS0wM2FkLTQ2MDAtOThkOS0wZGI4NDdjMzBjYzAiLCJleHAiOjB9" title="https://ppubs.uspto.gov/dirsearch-public/print/downloadBasicPdf/12239712?requestToken=eyJzdWIiOiI3OTM4NzBkYy02ZTJiLTRlNzQtOWFmMC01ZjViMmQyYjMyYTkiLCJ2ZXIiOiIzNTEwMDc4OS0wM2FkLTQ2MDAtOThkOS0wZGI4NDdjMzBjYzAiLCJleHAiOjB9">https://ppubs.uspto.gov/dirsearch-public/print/downloadBasicPdf/12239712?requestToken=eyJzdWIiOiI3OTM4NzBkYy02ZTJiLTRlNzQtOWFmMC01ZjViMmQyYjMyYTkiLCJ2ZXIiOiIzNTEwMDc4OS0wM2FkLTQ2MDAtOThkOS0wZGI4NDdjMzBjYzAiLCJleHAiOjB9</a>

Galmed Research And Development Granted U.S. Patent #12239712 Combination therapy for the treatment of liver disease

Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110424&amp;t=be2bearmibe3na1">and individual tickers.</a>
Here is a look at the most-searched stocks on Benzinga Pro for October 2024. Current prices and year-to-date performance are based on Nov. 1 and do not include dividends.
1. Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)
<ul>
<li>Current Price: $248.98</li>
<li>52-Week Range: $138.80 to $273.54</li>
<li>Year-to-Date Return: +0.2%</li>
<li><a href="https://www.benzinga.com/top-stories/24/08/40119459/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-july-2024-where-do-tesla-nvidia-apple-crow">July</a>/<a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/09/40691773/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-august-2024-where-do-tesla-n">August</a>/<a href="https://www.benzinga.com/top-stories/24/10/41150827/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-september-2024-where-do-tesla-nvidia-apple">September </a>Ranking: 1st/3rd/3rd</li>
</ul>
2. NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)
<ul>
<li>Current Price: $135.37</li>
<li>52-Week Range: $44.90 to $144.42</li>
<li>Year-to-Date Return: +181.0%</li>
<li>July/August/September Ranking: 2nd/1st/1st</li>
</ul>
3. Trump Media &amp; Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>)
<ul>
<li>Current Price: $30.56</li>
<li>52-Week Range: $11.75 to $79.38</li>
<li>Year-to-Date Return: +75.7%</li>
<li>July/August/September Ranking: Not in Top 20/Not in Top 20/20th</li>
</ul>
4. SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)
<ul>
<li>Current Price: $571.04</li>
<li>52-Week Range: $426.56 to $586.12</li>
<li>Year-to-Date Return: +20.8%</li>
<li>July/August/September Ranking: 3rd/2nd/2nd</li>
</ul>
5. Super Micro Computer Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>)
<ul>
<li>Current Price: $26.05</li>
<li>52-Week Range: $24.92 to $122.90</li>
<li>Year-to-Date Return: -8.8%</li>
<li>July/August/September Ranking: 19th/4th/7th</li>
</ul>
6. Bright Minds Biosciences Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRUG#NASDAQ">DRUG</a>)
<ul>
<li>Current Price: $48.18</li>
<li>52-Week Range: $0.93 to $79.02</li>
<li>Year-to-Date Return: +2,518.5%</li>
<li>July/August/September Ranking: Not in Top 20 in Any</li>
</ul>
7. Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>)
<ul>
<li>Current Price: $141.86</li>
<li>52-Week Range: $110.22 to $227.30</li>
<li>Year-to-Date Return: +2.4%</li>
<li>July/August/September Ranking: 14th/8th/Not in Top 20</li>
</ul>
8. Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>)
<ul>
<li>Current Price: $222.91</li>
<li>52-Week Range: $164.08 to $237.49</li>
<li>Year-to-Date Return: +20.1%</li>
<li>July/August/September Ranking: 7th/6th/4th</li>
</ul>
9. Tevogen Bio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>)
<ul>
<li>Current Price: $2.37</li>
<li>52-Week Range: $0.26 to $21.09</li>
<li>Year-to-Date Return: -78.7%</li>
<li>July/August/September Ranking: Not in Top 20 in Any</li>
</ul>
10. Oklo Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>)
<ul>
<li>Current Price: $21.67 </li>
<li>52-Week Range: $5.35 to $28.12 </li>
<li>Year-to-Date Return: +104.4% </li>
<li>July/August/September Ranking: Not in Top 20 in Any </li>
</ul>
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent110424">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Honorable Mentions:&nbsp;The following stocks were the 11th&nbsp;to 20th&nbsp;most-searched tickers on&nbsp;<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent090324&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>&nbsp;in October 2024.
11. Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)
12. Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>)
13. Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>)
14. Palantir Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>)
15. Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)
16. MicroStrategy Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>)
17. Genprex Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>)
18. SoFi Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOFI#NASDAQ">SOFI</a>)
19. Boeing Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>)
20. TeraWulf Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WULF#NASDAQ">WULF</a>)
Why It's Important: Tesla, regularly among the most searched tickers on the site, climbed the leaderboard to be the most-searched ticker on Benzinga Pro in October. The stock was third in the past two months, but ranked first in July. 
Nvidia ranked second in October, dropping from first place over the last two months. The technology giant briefly passed Apple and Microsoft to be the<a href="https://www.benzinga.com/markets/equities/24/10/41551461/nvidia-overtakes-apple-as-worlds-most-valuable-company-again"> most valuable company in the world.</a>
One of the biggest movers in October was Trump Media &amp; Technology Group, a media company co-founded by former President Donald Trump. The stock has surged in recent weeks ahead of Election Day. Trump's odds of winning the 2024 presidential election have <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41635149/2024-election-odds-on-polymarket-kalshi-show-trump-will-win-why-they-might-be-wrong">increased across prediction markets</a> and sports betting apps.
The stock has also been highlighted as a potential <a href="https://www.benzinga.com/general/politics/24/10/41630878/djt-short-squeeze-could-push-stock-to-60-if-trump-wins-but-analysis-says-loss-could-make-shares-">short-squeeze stock </a>with high short interest. A 2024 election win by Trump could see the stock shoot higher. Likewise, the stock could fall significantly if Trump loses the election.
Trump Media &amp; Technology Group will likely be among the most searched tickers on Benzinga Pro in November with Election Day happening on Nov. 5. The stock was the 20th most searched ticker in September and wasn't in the top 20 in August or July, ranking just outside the top 20.
The SPDR S&amp;P 500 ETF Trust falls to fourth place from second in the past two months, likely due more to the surge in interest in the stocks mentioned above and not less interest in the S&amp;P 500 market index. Although it should be noted that the Invesco QQQ Trust ETF, which tracks the Nasdaq 100 Index, fell from sixth place to 15th in October, potentially signaling less interest in ETFs and market indexes.
Other newcomers to the top 10 were Bright Minds Biosciences, Tevogen Bio and Oklo, who have each not previously been among the top 20 most-searched tickers in any given month. Tevogen shares have fallen significantly in 2024, while Bight Minds Sciences and Oklo are each up over 100% in 2024.
Advanced Micro Devices also returned to the top 10, ranking seventh, which comes after falling out of the top 20 in September. The stock has regularly gone back and forth between the top 10 and top 20 each month in 2024.
Dropping out of the top 10 along with Invesco QQQ were Wheeler Real Estate Investment Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WHLR#NASDAQ">WHLR</a>), Galmed Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLMD#NASDAQ">GLMD</a>), Intel Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) and Intuitive Machines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NASDAQ">LUNR</a>). &nbsp;
Overall the month of October saw five of the same top 10 tickers from September and eight of the top 20 tickers from September.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/education/24/10/41665149/these-10-stocks-were-s-p-500s-top-performers-in-bidens-first-year-could-the-trend-continue-if-h">These 10 Stocks Were S&amp;P 500&#8217;s Top Performers In Biden&#8217;s First Year: Could Trend Continue If Harris Wins 2024 Election?</a></li>
</ul>

EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In October 2024 — Where Do Tesla, Nvidia, Apple, DJT Stock Rank?

Buybacks

Galmed Pharmaceuticals Shareholders Approve Proposal At Special Meeting; Amends Equity Purchase Agreement With Yorkville To Increase Commitment Amount From $10M To $20M

Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent100224&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">and individual tickers.</a>
Here is a look at the most-searched stocks on Benzinga Pro for September 2024. Current prices and year-to-date performance are based on Sept. 30 and do not include dividends.
1. NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)
<ol></ol>
<ol></ol>
<ol></ol>
<ol></ol>
<ul>
<li>Current Price: $121.44</li>
<li>52-Week Range: $39.23 to $140.76</li>
<li>Year-to-Date Return: +152.1%</li>
<li><a href="https://www.benzinga.com/top-stories/24/07/39579249/exclusive-top-10-most-searched-tickers-on-benzinga-pro-in-june-where-do-nvidia-gamestop-tesla-apple">June</a>/<a href="https://www.benzinga.com/top-stories/24/08/40119459/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-july-2024-where-do-tesla-nvidia-apple-crow">July</a>/<a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/09/40691773/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-august-2024-where-do-tesla-n">August </a>Ranking: 1st/2nd/1st</li>
</ul>
2. SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)
<ul>
<li>Current Price: $573.76</li>
<li>52-Week Range: $409.22 to $574.71</li>
<li>Year-to-Date Return: +21.4%</li>
<li>June/July/August Ranking: 3rd/3rd/2nd</li>
</ul>
3. Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)
<ul>
<li>Current Price: $261.63</li>
<li>52-Week Range: $138.80 to $271.00</li>
<li>Year-to-Date Return: +5.3%</li>
<li>June/July/August Ranking: 4th/1st/3rd</li>
</ul>
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent100224">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
4. Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>)
<ul>
<li>Current Price: $233.00</li>
<li>52-Week Range: $164.08 to $237.23</li>
<li>Year-to-Date Return: +25.5%</li>
<li>June/July/August Ranking: 5th/7th/6th</li>
</ul>
5. Wheeler Real Estate Investment Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WHLR#NASDAQ">WHLR</a>)
<ul>
<li>Current Price: $8.09</li>
<li>52-Week Range: $2.90 to $1,126.80</li>
<li>Year-to-Date Return: -92.8%</li>
<li>June/July/August Ranking: Not in Top 20 in any</li>
</ul>
6. Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)
<ul>
<li>Current Price: $488.07</li>
<li>52-Week Range: $342.35 to $503.52</li>
<li>Year-to-Date Return: +21.2%</li>
<li>June/July/August Ranking: 11th/11th/9th</li>
</ul>
7. Super Micro Computer (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>)
<ul>
<li>Current Price: $416.40</li>
<li>52-Week Range: $226.59 to $1,229.00</li>
<li>Year-to-Date Return: +45.9%</li>
<li>June/July/August Ranking: 10th/19th/4th</li>
</ul>
8. Galmed Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLMD#NASDAQ">GLMD</a>)
<ul>
<li>Current Price: $6.86</li>
<li>52-Week Range: $2.73 to $23.80</li>
<li>Year-to-Date Return: +29.9%</li>
<li>June/July/August Ranking: Not in Top 20 in any</li>
</ul>
9. Intel Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>)
<ul>
<li>Current Price: $23.46</li>
<li>52-Week Range: $18.51 to $51.28</li>
<li>Year-to-Date Return: -50.9%</li>
<li>June/July/August Ranking: Not in Top 20 in any</li>
</ul>
10. Intuitive Machines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NASDAQ">LUNR</a>)
<ul>
<li>Current Price: $8.05</li>
<li>52-Week Range: $2.09 to $13.25</li>
<li>Year-to-Date Return: +241.1%</li>
<li>June/July/August Ranking: Not in Top 20/Not in Top 20/20th</li>
</ul>
Honorable Mentions:&nbsp;The following stocks were the 11th&nbsp;to 20th&nbsp;most-searched tickers on&nbsp;<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent090324&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>&nbsp;in September 2024.
11. Summit Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>)
12. Palantir Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>)
13. Micron Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>)
14. Tenon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNON#NASDAQ">TNON</a>)
15. CN Energy Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNEY#NASDAQ">CNEY</a>)
16. Quhuo Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QH#NASDAQ">QH</a>)
17. ENDRA Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDRA#NASDAQ">NDRA</a>):
18. Applied Digital Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>)
19. Immuneering Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMRX#NASDAQ">IMRX</a>)
20. Trump Media &amp; Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>)
Why It&#8217;s Important:&nbsp;Nvidia was the top searched stock on Benzinga Pro for the month of September once again. The stock has ranked first or second for every month tracked since February, sometimes alternating with SPY or Tesla.
The SPDR S&amp;P 500 ETF Trust ranked second for a second straight month, which comes as the S&amp;P 500 tracking index hit new all-time highs in the month of September.
Tesla, which topped the month of July, has ranked third for two straight weeks. The stock has ranked among the top four stocks searched in each month tracked in 2024.
The bigger story in September were the newcomers and the stocks that dropped off.
Newcomers to the top 10 included Wheeler Real Estate, Galmed, Intel and Intuitive. Of the four stocks, only Intuitive had ranked in the top 20 over the last three months. The newcomers all had catalysts in the last month that made their stocks highly volatile.
On the 11th through 20th portion of the list, the stocks were all different from the previous month with Intuitive moving to the top 10 and Palantir going from 7th to 12th and the other stocks all new to the top 20.
Several of the companies ranked in the bottom part of the top 20 are penny stocks trading at less than $5 per share that saw wide moves that saw increased interest from Benzinga traders.
One of the bigger names to make the top 20, by name recognition, is Trump Media &amp; Technology Group, the company that counts former President Donald Trump as a co-founder. The stock has been highly volatile during the 2024 election cycle.
Dropping out of the top 10 were Lumen Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUMN#NYSE">LUMN</a>), Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>), Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) and the aforementioned Palantir.
Other big names that exited the top 20 include Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) that was 13th in August and fell to 24th to narrowly miss the list.
Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), which has frequently appeared in the top 20 and was ranked 15th in August dropped out of the top 20.
Overall the month of September saw six of the same top 10 tickers from August and eight of the top 20 tickers from August.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/exclusives/24/07/39603613/exclusive-top-10-most-searched-tickers-on-benzinga-pro-in-first-half-2024-where-do-nvidia-tesla-pala">EXCLUSIVE: Top 10 Most Searched Tickers On Benzinga Pro In First Half 2024 – Where Do Nvidia, Tesla, Palantir, GameStop Rank?</a></li>
</ul>
Image: Shutterstock

EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In September 2024 – Where Do Tesla, Nvidia, Apple, DJT Stock Rank?

WIIM

Galmed Pharmaceuticals shares are trading lower. The company announced that results of its Phase 3 trial of Aramchol in 150 patients with NASH and fibrosis has been published in Hepatology.

<ul>
<li>The paper re-iterates the significant&nbsp;anti-fibrotic effect of Aramchol 300mg BID in patients with metabolic dysfunction associated steatohepatitis (MASH)</li>
<li>Data is confirmed using 3 objective measurements; NASH&nbsp;CRN, paired ranked reading, and Artificial Intelligence (AI) quantitative digital analysis</li>
<li>Continuous&nbsp;histological fibrosis scores generated in antifibrotic trials by digital pathology images analysis (DIA) quantify antifibrotic effects with greater sensitivity and larger dynamic range than Conventional Pathology</li>
</ul>
TEL AVIV, Israel, Sept. 25, 2024 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLMD#NASDAQ">GLMD</a>) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibro-inflammatory diseases announced today that the one-year results of the Open-Label part (ARCON ) of its global Phase 3 trial of Aramchol in 150 patients with NASH and fibrosis (ARMOR) have been published in&nbsp;<a href="https://journals.lww.com/hep/abstract/9900/aramchol_improves_hepatic_fibrosis_in_metabolic.930.aspx">Hepatology</a>.&nbsp;

Galmed 1-Year Results Of The Open-Label Part Of Its Global Phase 3 Trial Of Aramchol In 150 Patients With NASH And Fibrosis Have Been Published In Hepatology

Insider Trades

Masaya Otsuka Reported a 9.9% Passive Stake In Galmed Pharmaceuticals In A 13G Filing

Each week,&nbsp;Benzinga's Stock Whisper Index&nbsp;uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the&nbsp;<a href="https://www.benzinga.com/topic/stock-whisper-index" target="_blank" rel="noreferrer noopener">surface and deserve attention</a>.
Investors are constantly on the hunt for undervalued, under-followed and emerging stocks. With countless methods available to retail traders, the challenge often lies in sifting through the abundance of information to uncover new opportunities and understand why certain stocks should be of interest.
Here&#8217;s a look at the Benzinga Stock Whisper Index for the week of Sept. 20:
Barrick Gold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GOLD#NYSE">GOLD</a>): The gold-mining company saw increased interest from readers this week on the heels of a 50 basis point cut to interest rates by the Federal Reserve, which saw gold prices rise. The interest also comes after Barrick Gold CEO Mark Bristow spoke at the Gold Forum Americas earlier this week and<a href="https://www.benzinga.com/news/24/09/40915786/barrick-forecasts-strong-organic-growth-by-2030-ceo-bristow-touts-undervaluation"> said the company expects </a>30% growth in gold-equivalent ounces by the end of the decade from its existing assets. 
Bristow's comments emphasized the company's current mines and those in development, as the industry experiences a surge in merger and acquisition activity. The CEO also highlighted how the company is expanding its copper portfolio, which could be something exciting to watch for investors.
Barrick shares were down 2% over the last five trading days, as seen on the <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092024&amp;t=be2bearmibe3na1">Benzinga Pro chart</a> below. The stock is up 14% year-to-date in 2024.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092024&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="999" height="483" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121633/Screenshot-183.png" alt="" class="wp-image-558808" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121633/Screenshot-183.png 999w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121633/Screenshot-183-300x145.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121633/Screenshot-183-768x371.png 768w" sizes="(max-width: 999px) 100vw, 999px" /></a></figure>
Galmed Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLMD#NASDAQ">GLMD</a>): The biopharmaceutical company <a href="https://www.benzinga.com/news/24/09/40941193/galmed-pharmaceuticals-stock-is-soaring-thursday-heres-why">saw shares soar </a>during the week after an announcement on drug development activities. Galmed plans to add drug developments that target cardiac fibrosis and colorectal and hepatic cancers. The company will release data from the studies during the fourth quarter.
"The conditions Galmed plans to focus upon in the coming years are major public health problems impacting millions of people worldwide and posing huge financial burden on health providers," Galmed CEO Allen Baharaff said.
Large interest in Galmed saw shares halted several times during the trading week. Helping with volatility in the biopharmaceutical company is the low-float of the stock with around 625,000 shares available according to Benzinga Pro. Low-float stocks can often see high volatility on company announcements.
The stock was up 160% over the last five days and up nearly 100% year-to-date in 2024.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092024&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="993" height="502" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121656/Screenshot-184.png" alt="" class="wp-image-558810" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121656/Screenshot-184.png 993w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121656/Screenshot-184-300x152.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121656/Screenshot-184-768x388.png 768w" sizes="(max-width: 993px) 100vw, 993px" /></a></figure>
Read Also:&nbsp;<a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/09/40691773/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-august-2024-where-do-tesla-n" target="_blank" rel="noreferrer noopener">EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In August 2024 – Where Do Tesla, Nvidia, Apple, AMD Stock Rank?</a>
ServiceNow Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>): The software company is seeing a large increase in interest from readers ahead of its third-quarter financial results. Analysts expect the company to report revenue of $2.74 billion, up from $2.29 billion in last year's third quarter.
The company has beaten analyst revenue estimates in six straight quarters. Analysts expect the company to report earnings per share of $3.46, up from $2.92 in last year's third quarter. ServiceNow has beaten earnings estimates from analysts in more than 20 straight quarters.
The company's earnings report will show investors and analysts whether revenue growth and AI platform demand are continuing to strengthen. The company saw subscription revenue up 23% year-over-year in <a href="https://www.benzinga.com/news/earnings/24/07/39944577/servicenow-q2-earnings-revenue-beat-eps-beat-servicenow-intends-to-reinvent-every-workflow-in-every">the second quarter </a>and said it was helping meet demand from CEOs looking for new growth as ServiceNow reinvents "every workflow, in every company, in every industry with GenAI at the core."
ServiceNow shares are up 4% over the last five days and up 34% year-to-date.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092024&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="997" height="514" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121712/Screenshot-185.png" alt="" class="wp-image-558811" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121712/Screenshot-185.png 997w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121712/Screenshot-185-300x155.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121712/Screenshot-185-768x396.png 768w" sizes="(max-width: 997px) 100vw, 997px" /></a></figure>
Deutsche Bank (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DB#NYSE">DB</a>): It's not every week that a bank stock makes its way on the Stock Whisper Index, but here we are. Deutsche Bank saw strong interest from readers, which could be due to bank stocks getting a lift after the <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/09/40928301/interest-rates-in-free-fall-what-it-means-for-mortgages-credit-cards-and-your-wallet-a">interest rate cut was announced.</a> 
The move could see lenders have their balance sheets strengthened going forward and see increased demand for loan activity. Deutsche Bank reports third-quarter financial results in October and could comment on demand and what the future looks like for the company and the sector.
Shares were up 5% over the last five days and 24% year-to-date.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092024&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="999" height="504" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121726/Screenshot-186.png" alt="" class="wp-image-558812" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121726/Screenshot-186.png 999w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121726/Screenshot-186-300x151.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121726/Screenshot-186-768x387.png 768w" sizes="(max-width: 999px) 100vw, 999px" /></a></figure>
Stryker Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>): The medical equipment company saw strong interest from readers during the week, which comes on the heels of acquisition announcements, new products <a href="https://www.benzinga.com/quote/SYK/analyst-ratings">and analyst notes</a>. 
The company recently unveiled new foot and ankle solutions that can help restore limb length. Stryker closed its acquisition of privately held care.ai, a company helping with AI-assisted virtual care workflows and smart room technology. The company said the acquisition will help accelerate its digital vision and could expand its healthcare IT business. 
On Friday, Stryker closed its acquisition of NICO Corporation, a company with a surgery method for tumor and intracerebral hemorrhage procedures. Stryker also announced an acquisition of pain management company Vertos Medical in August. Together, the acquisitions and new products could have investors excited about the company's future and its potential diversification efforts.
Piper Sandler recently maintained an Overweight rating and a $380 price target on the stock. Wolfe Research initiated coverage with an Outperform rating and a $405 price target.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092024&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="993" height="501" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121742/Screenshot-187.png" alt="" class="wp-image-558813" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121742/Screenshot-187.png 993w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121742/Screenshot-187-300x151.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121742/Screenshot-187-768x387.png 768w" sizes="(max-width: 993px) 100vw, 993px" /></a></figure>
Stay tuned for next week's report, and follow Benzinga Pro for all the latest headlines and&nbsp;<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent091324&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">top market-moving stories here.</a>
Read the latest Stock Whisper Index reports here:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/08/40420145/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noreferrer noopener">August 16</a></li>
<li><a href="https://www.benzinga.com/top-stories/24/08/40531771/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noreferrer noopener">August 23</a></li>
<li><a href="https://www.benzinga.com/exclusives/24/08/40653930/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noreferrer noopener">August 30</a></li>
<li><a href="https://www.benzinga.com/general/biotech/24/09/40752686/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noreferrer noopener">September 6</a></li>
<li><a href="https://www.benzinga.com/top-stories/24/09/40855829/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet">September 13 </a></li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/40838414/gold-miners-eye-best-1-day-rally-in-6-months-as-gold-hits-fresh-record-highs-todays-environment-">Gold Miners Eye Best 1-Day Rally In 6 Months As Gold Hits Fresh Record Highs: &#8216;Today&#8217;s Environment Closely Resembles The 1970s&#8217;</a></li>
</ul>
Photo: Benzinga

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet

Galmed Pharmaceuticals Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLMD#NASDAQ">GLMD</a>) shares are surging Thursday after the company&nbsp;announced plans to broaden its drug development activities <a href="https://www.benzinga.com/pressreleases/24/09/n40935244/galmed-announces-an-expansion-of-its-activities-to-cancer-and-major-cardiometabolic-diseases">over the next two years</a>.
What Happened: Galmed announced that it plans to expand its drug development activities by adding two additional programs.
One program aims to identify novel Aramchol-based drug combinations to overcome resistance to standard-of-care oncological treatments for patients with advanced colorectal and hepatic cancers. The other program is expected to help discover new methods to allow the development of a novel Aramchol-based drug combination targeting cardiac fibrosis.
The clinical-stage biopharmaceutical company said it&nbsp;plans to release new data from in-vitro and ex-vivo studies on the aforementioned programs during the&nbsp;fourth quarter.
&#8220;The conditions Galmed plans to focus upon in the coming years are major public health problems impacting millions of people worldwide and posing huge financial burden on health providers,&#8221; said Allen Baharaff, president and CEO of Galmed Pharmaceuticals.
&#8220;SCD1 is a key enzyme that critically regulates many physiological processes, thereby promoting the progression of cardiovascular, cancer and neurodegenerative diseases. We are leveraging on two decades of development of the most clinically advanced SCD1 inhibitor (Aramchol) to date as we broaden our drug development activities.&#8221;
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/09/40939795/1-8m-bet-on-singular-genomics-check-out-these-3-stocks-executives-are-buying">$1.8M Bet On Singular Genomics? Check Out These 3 Stocks Executives Are Buying</a>
Galmed Pharmaceuticals is a very low-float stock with approximately 625,000 shares available for public trading, per&nbsp;<a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.&nbsp;The company also had a market cap of less than $4.5 million as of Wednesday's close.&nbsp;Low-float, micro-cap stocks can be extremely volatile, which may help explain some of Thursday's surge.
Galmed&#8217;s average session volume over a 100-day period is approximately 1.711 million. Thursday&#8217;s trading volume has already crossed 16 million at the time of writing, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
GLMD Price Action: <a href="http://benzinga.com/quote/glmd">Galmed shares</a> were up 53.6% at $10.60 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: 3844328 from Pixabay.

Movers

Galmed Pharmaceuticals Stock Is Soaring Thursday: Here's Why

Galmed Pharmaceuticals Shares Halted To The Upside; Stock Now Up 67.54%

Galmed Pharmaceuticals shares are trading higher after the company announced plans to broaden its drug development activities with two additional programs over the next two years.

Small Cap

Press Releases

Galmed Announces an Expansion of its Activities to Cancer and major Cardiometabolic Diseases

How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs

Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology

Galmed Pharmaceuticals Secures New Patent Grant Extending Aramchol's Patent Protection to 2039, Strengthening Leadership in NASH/MASH Combination Therapy

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024

Galmed Announces Positive Part 1 Results from the AM-001 Study of Aramchol Meglumine, an Enhanced Formulation of the Most Clinically Advanced SCD1 Inhibitor

Galmed Unveils Novel Pharmacodynamic Blood Markers for Aramchol, the Most Clinically Advanced SCD1 Inhibitor

Galmed Pharmaceuticals Launches VCU Collaboration to Tackle Drug Resistance in GI Cancers

ONCY

TSX:ONC

Maxim Group

Canaccord Genuity

매 거래일마다 수백 개의 헤드라인과 보도자료가 벤징가 프로에 올라와, 트레이더들이 전체 시장과 <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110424&amp;t=be2bearmibe3na1" target="_blank" rel="noopener" data-google-interstitial="false">개별 종목</a>에 대한 최신 뉴스를 확인할 수 있는 소스이다.
2024년 10월에 벤징가 프로에서 가장 많이 검색된 주식들을 살펴보겠다. 현재 가격과 연초 대비 실적은 11월 1일 기준이며 배당금은 포함되지 않았다.
1. 테슬라 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)
&#8211; 현재 가격: $248.98 
&#8211; 52주 가격 범위: $138.80 ~ $273.54 
&#8211; 연초 대비 수익률: +0.2% 
&#8211; <a href="https://www.benzinga.com/top-stories/24/08/40119459/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-july-2024-where-do-tesla-nvidia-apple-crow" target="_blank" rel="noopener" data-google-interstitial="false">7월</a>/<a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/09/40691773/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-august-2024-where-do-tesla-n" target="_blank" rel="noopener" data-google-interstitial="false">8월</a>/<a href="https://www.benzinga.com/top-stories/24/10/41150827/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-september-2024-where-do-tesla-nvidia-apple" target="_blank" rel="noopener" data-google-interstitial="false">9월</a> 순위: 1위/3위/3위
2. 엔비디아 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)
&#8211; 현재 가격: $135.37 
&#8211; 52주 가격 범위: $44.90 ~ $144.42 
&#8211; 연초 대비 수익률: +181.0% 
&#8211; 7월/8월/9월 순위: 2위/1위/1위
3. 트럼프 미디어 앤 테크놀로지 그룹 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>)
&#8211; 현재 가격: $30.56 
&#8211; 52주 가격 범위: $11.75 ~ $79.38 
&#8211; 연초 대비 수익률: +75.7% 
&#8211; 7월/8월/9월 순위: 상위 20위 미포함/상위 20위 미포함/20위
4. SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)
&#8211; 현재 가격: $571.04 
&#8211; 52주 가격 범위: $426.56 ~ $586.12 
&#8211; 연초 대비 수익률: +20.8% 
&#8211; 7월/8월/9월 순위: 3위/2위/2위
5. 슈퍼 마이크로 컴퓨터 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>)
&#8211; 현재 가격: $26.05 
&#8211; 52주 가격 범위: $24.92 ~ $122.90 
&#8211; 연초 대비 수익률: -8.8% 
&#8211; 7월/8월/9월 순위: 19위/4위/7위
6. 브라이트 마인즈 바이오사이언시스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRUG#NASDAQ">DRUG</a>)
&#8211; 현재 가격: $48.18 
&#8211; 52주 가격 범위: $0.93 ~ $79.02 
&#8211; 연초 대비 수익률: +2,518.5% 
&#8211; 7월/8월/9월 순위: 상위 20위 미포함/상위 20위 미포함/상위 20위 미포함
7. 어드밴스드 마이크로 디바이시스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>)
&#8211; 현재 가격: $141.86 
&#8211; 52주 가격 범위: $110.22 ~ $227.30 
&#8211; 연초 대비 수익률: +2.4% 
&#8211; 7월/8월/9월 순위: 14위/8위/상위 20위 미포함
8. 애플 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>)
&#8211; 현재 가격: $222.91 
&#8211; 52주 가격 범위: $164.08 ~ $237.49 
&#8211; 연초 대비 수익률: +20.1% 
&#8211; 7월/8월/9월 순위: 7위/6위/4위
9. 테보젠 바이오 홀딩스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>)
&#8211; 현재 가격: $2.37 
&#8211; 52주 가격 범위: $0.26 ~ $21.09 
&#8211; 연초 대비 수익률: -78.7% 
&#8211; 7월/8월/9월 순위: 상위 20위 미포함/상위 20위 미포함/상위 20위 미포함
10. 오클로 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>)
&#8211; 현재 가격: $21.67 
&#8211; 52주 가격 범위: $5.35 ~ $28.12 
&#8211; 연초 대비 수익률: +104.4% 
&#8211; 7월/8월/9월 순위: 상위 20위 미포함/상위 20위 미포함/상위 20위 미포함
주목할 만한 주식들:다음 주식들은 2024년 10월 <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent090324&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>에서 11위에서 20위까지 가장 많이 검색된 종목들이다.
11. 아마존닷컴 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)
12. 마이크로소프트 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>)
13. 메타 플랫폼 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>)
14. 팔란티어 테크놀로지스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>)
15. Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)
16. 마이크로스트레티지 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>)
17. 젠프렉스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>)
18. 소파이 테크놀로지스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOFI#NASDAQ">SOFI</a>)
19. 보잉 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>)
20. 테라울프 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WULF#NASDAQ">WULF</a>)
중요한 이유 (Why It&#8217;s Important): 테슬라는 사이트에서 가장 많이 검색되는 티커 중 하나로, 10월에 벤징가 프로에서 가장 많이 검색된 종목이 되었다. 주가는 지난 두 달 동안 3위를 기록했으나, 7월에는 1위를 차지한 바 있다.
엔비디아는 10월에 2위로 순위가 하락했으며, 지난 두 달 동안 1위를 기록했다. 이 기술 대기업은 잠시 동안 애플과 마이크로소프트를 제치고 <a href="https://www.benzinga.com/markets/equities/24/10/41551461/nvidia-overtakes-apple-as-worlds-most-valuable-company-again" target="_blank" rel="noopener" data-google-interstitial="false">세계에서 가장 가치 있는 회사</a>로 등극하기도 했다.
10월의 가장 큰 변동 종목 중 하나는 트럼프 미디어 앤 테크놀로지 그룹으로, 전 대통령 도널드 트럼프가 공동 설립한 미디어 회사이다. 주식은 선거일을 앞두고 최근 몇 주 동안 급등했다. 트럼프의 2024년 대통령 선거 승리 확률은 <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41635149/2024-election-odds-on-polymarket-kalshi-show-trump-will-win-why-they-might-be-wrong" target="_blank" rel="noopener" data-google-interstitial="false">예측 시장</a>과 스포츠 베팅 앱에서 상승했다.
이 주식은 또한 높은 공매도 비율을 가진 <a href="https://www.benzinga.com/general/politics/24/10/41630878/djt-short-squeeze-could-push-stock-to-60-if-trump-wins-but-analysis-says-loss-could-make-shares-" target="_blank" rel="noopener" data-google-interstitial="false">공매도 압박 종목(</a><a href="https://www.benzinga.com/general/politics/24/10/41630878/djt-short-squeeze-could-push-stock-to-60-if-trump-wins-but-analysis-says-loss-could-make-shares-" target="_blank" rel="noopener" data-google-interstitial="false">short-squeeze</a><a href="https://www.benzinga.com/general/politics/24/10/41630878/djt-short-squeeze-could-push-stock-to-60-if-trump-wins-but-analysis-says-loss-could-make-shares-" target="_blank" rel="noopener" data-google-interstitial="false">)</a>으로 주목받았다. 트럼프가 2024년 선거에서 승리할 경우 주가는 급등할 수 있다. 반대로, 트럼프가 선거에서 패할 경우 주가는 크게 하락할 수 있다.
트럼프 미디어 앤 테크놀로지 그룹은 11월에도 벤징가 프로에서 가장 많이 검색된 티커 중 하나가 될 가능성이 높으며, 선거일은 11월 5일이다. 이 주식은 9월에 20위에 올랐고, 8월이나 7월에는 상위 20위에 포함되지 않았다.
SPDR S&amp;P 500 ETF Trust는 지난 두 달간 2위에서 4위로 하락했으며, 이는 위에 언급된 주식들에 대한 관심 증가 때문일 가능성이 크고, S&amp;P 500 시장 지수에 대한 관심 감소 때문은 아니다. 또한, 나스닥 100 지수를 추적하는 Invesco QQQ Trust ETF는 6위에서 15위로 하락하여, ETF와 시장 지수에 대한 관심이 줄어들었을 가능성을 나타낸다.
상위 10위에 새롭게 진입한 주식은 브라이트 마인즈 바이오사이언시스, 테보젠 바이오 및 오클로로, 이들은 이전에 어떤 달에도 상위 20위에 포함된 적이 없다. 테보젠의 주식은 2024년에 크게 하락했으며, 브라이트 마인즈와 오클로는 각각 2024년에 100% 이상 상승했다.
AMD도 7위로 상위 10위에 재진입했으며, 이는 9월에 상위 20위에서 탈락한 후의 일이다. 이 주식은 2024년 동안 매달 상위 10위와 상위 20위 사이에서 계속 오르락내리락하고 있다.
상위 10위에서 Invesco QQQ와 함께 탈락한 주식은 휠러 리얼 에스테이트 인베스트먼트 트러스트(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WHLR#NASDAQ">WHLR</a>), 갈메드 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLMD#NASDAQ">GLMD</a>), 인텔(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) 및 인튜이티브 머신스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NASDAQ">LUNR</a>)이다.
전반적으로 10월 한 달 동안 9월의 상위 10위 주식 중 5개가 동일하게 유지되었고, 9월의 상위 20위 주식 중 8개가 동일하게 유지되었다.
다음 기사:
<ul class="block core-block">
<li><a href="https://www.benzinga.com/general/education/24/10/41665149/these-10-stocks-were-s-p-500s-top-performers-in-bidens-first-year-could-the-trend-continue-if-h" target="_blank" rel="noopener" data-google-interstitial="false">These 10 Stocks Were S&amp;P 500's Top Performers In Biden's First Year: Could Trend Continue If Harris Wins 2024 Election?</a></li>
</ul>
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

매일 거래일마다 벤징가 프로(Benzinga Pro)에서 수백 개의 헤드라인과 보도자료가 올라온다. 이는 트레이더들이 전체 시장 및 <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent100224&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">개별 종목</a>에 대한 최신 뉴스를 확인할 수 있는 소스이다.
2024년 9월에 Benzinga Pro에서 가장 많이 검색된 주식들을 살펴보겠다. 현재 가격과 연초 대비 성과는 9월 30일 기준이며 배당금은 포함되지 않았다.
1. 엔비디아 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)
<ul>
<li>현재 가격: $121.44</li>
<li>52주 최고가/최저가: $39.23 ~ $140.76</li>
<li>연초 대비 수익률: +152.1%</li>
<li><a href="https://www.benzinga.com/top-stories/24/07/39579249/exclusive-top-10-most-searched-tickers-on-benzinga-pro-in-june-where-do-nvidia-gamestop-tesla-apple" target="_blank" rel="noopener" data-google-interstitial="false">6월</a>/<a href="https://www.benzinga.com/top-stories/24/08/40119459/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-july-2024-where-do-tesla-nvidia-apple-crow" target="_blank" rel="noopener" data-google-interstitial="false">7월</a>/<a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/09/40691773/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-august-2024-where-do-tesla-n" target="_blank" rel="noopener" data-google-interstitial="false">8월 </a>순위: 1위/2위/1위</li>
</ul>
2. SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)
<ul>
<li>현재 가격: $573.76</li>
<li>52주 최고가/최저가: $409.22 ~ $574.71</li>
<li>연초 대비 수익률: +21.4%</li>
<li>6월/7월/8월 순위: 3위/3위/2위</li>
</ul>
3. 테슬라 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)
<ul>
<li>현재 가격: $261.63</li>
<li>52주 최고가/최저가: $138.80 ~ $271.00</li>
<li>연초 대비 수익률: +5.3%</li>
<li>6월/7월/8월 순위: 4위/1위/3위</li>
</ul>
4. 애플 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>)
<ul>
<li>현재 가격: $233.00</li>
<li>52주 최고가/최저가: $164.08 ~ $237.23</li>
<li>연초 대비 수익률: +25.5%</li>
<li>6월/7월/8월 순위: 5위/7위/6위</li>
</ul>
5. 휠러 리얼 에스테이트 인베스트 트러스트 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WHLR#NASDAQ">WHLR</a>)
<ul>
<li>현재 가격: $8.09</li>
<li>52주 최고가/최저가: $2.90 ~ $1,126.80</li>
<li>연초 대비 수익률: -92.8%</li>
<li>6월/7월/8월 순위: 20위 미만</li>
</ul>
6. Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)
<ul>
<li>현재 가격: $488.07</li>
<li>52주 최고가/최저가: $342.35 ~ $503.52</li>
<li>연초 대비 수익률: +21.2%</li>
<li>6월/7월/8월 순위: 11위/11위/9위</li>
</ul>
7. 슈퍼 마이크로 컴퓨터 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>)
<ul>
<li>현재 가격: $416.40</li>
<li>52주 최고가/최저가: $226.59 ~ $1,229.00</li>
<li>연초 대비 수익률: +45.9%</li>
<li>6월/7월/8월 순위: 10위/19위/4위</li>
</ul>
8. 갈메드 파마슈티컬스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLMD#NASDAQ">GLMD</a>)
<ul>
<li>현재 가격: $6.86</li>
<li>52주 최고가/최저가: $2.73 ~ $23.80</li>
<li>연초 대비 수익률: +29.9%</li>
<li>6월/7월/8월 순위: 20위 미만</li>
</ul>
9. 인텔 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>)
<ul>
<li>현재 가격: $23.46</li>
<li>52주 최고가/최저가: $18.51 ~ $51.28</li>
<li>연초 대비 수익률: -50.9%</li>
<li>6월/7월/8월 순위: 20위 미만</li>
</ul>
10. 인튜이티브 머신스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NASDAQ">LUNR</a>)
<ul>
<li>현재 가격: $8.05</li>
<li>52주 최고가/최저가: $2.09 ~ $13.25</li>
<li>연초 대비 수익률: +241.1%</li>
<li>6월/7월/8월 순위: 20위 미만/20위 미만/20위</li>
</ul>
순위 밖의 주식들: 다음 주식들이 2024년 9월에 Benzinga Pro에서 11위에서 20위까지 가장 많이 검색된 종목들다.
11. 서밋 테라퓨틱스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>)
12. 팔란티어 테크놀로지스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>)
13. 마이크론 테크놀로지 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>)
14. 테논 메디컬 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNON#NASDAQ">TNON</a>)
15. CN 에너지 그룹 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNEY#NASDAQ">CNEY</a>)
16. 취후오 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QH#NASDAQ">QH</a>)
17. 엔드라 라이프 사이언스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDRA#NASDAQ">NDRA</a>):
18. 어플라이드 디지털 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>)
19. 이뮤니어링 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMRX#NASDAQ">IMRX</a>)
20. 트럼프 미디어 앤 테크놀로지 그룹 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>)
중요성 (Why It's Important): 엔비디아는 9월 한 달 동안 Benzinga Pro에서 가장 많이 검색된 주식으로 다시 한번 선정되었다. 이 주식은 2월 이후로 매달 1위 또는 2위를 기록하고 있으며, 때때로 SPY 또는 테슬라와 교대로 1위에 올랐다.
SPDR S&amp;P 500 ETF Trust는 9월에 S&amp;P 500 추적 지수가 사상 최고치를 기록하면서 2위를 차지했다.
테슬라는 7월에 1위를 차지한 이후 두 주 연속 3위를 기록했다. 이 주식은 2024년 동안 매달 검색된 상위 4개의 주식 중 하나로 자리 잡았다.
9월의 큰 관심은 신규 진입 주식들과 순위에서 떨어진 주식들이었다.
신규 진입자로는 휠러 리얼 에스테이트, 갈메드, 인텔 및 인튜이티브가 포함되었다. 이 4개 주식 중에서 인튜이티브만이 지난 3개월 간 상위 20위에 랭크된 바 있다. 이 신규 진입자들은 모두 지난달에 주식을 크게 변동시킨 촉매제가 있었다.
11위에서 20위까지의 목록에서도 이전 달과는 모든 주식이 달랐으며 인튜이티브는 상위 10위로 올라갔고, 팔란티어는 7위에서 12위로 하락했으며 나머지 주식들은 모두 상위 20위에 신규로 진입했다.
상위 20위의 하위 주식들 중 일부는 주가가 $5 이하로 거래되는 저가 주식들이며, 이들 주식은 큰 변동성을 보이며 Benzinga 트레이더들의 관심이 증가했다.
상위 20위에 이름 인지도로 들어온 큰 회사는 트럼프 미디어 앤 테크놀로지 그룹으로, 전 대통령 도널드 트럼프가 공동 설립자이다. 이 주식은 2024년 선거 주기 동안 매우 변동성이 컸다.
상위 10위에서 떨어진 주식들은 루멘 테크놀로지스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUMN#NYSE">LUMN</a>), 어드밴스드 마이크로 디바이시스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>), 지오백스 랩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) 및 앞서 언급한 팔란티어이다.
상위 20위에서 빠진 다른 큰 이름들은 8월에 13위였던 아마존닷컴(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)으로, 24위로 하락하여 리스트에 아슬아슬하게 들지 못했다.
메타 플랫폼스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>)는 상위 20위에 자주 올라온 주식으로 8월에는 15위였으나 상위 20위에서 제외되었다.
전반적으로 9월에는 8월과 같은 상위 10개의 종목이 6개 있었고, 8월의 상위 20개 종목 중 8개가 포함되었다.
다음 읽기: 
<ul>
<li><a href="https://www.benzinga.com/exclusives/24/07/39603613/exclusive-top-10-most-searched-tickers-on-benzinga-pro-in-first-half-2024-where-do-nvidia-tesla-pala">독점: 2024년 상반기 가장 많이 검색된 종목 TOP 10 – 엔비디아, 테슬라, 팔란티어, 게임스탑의 순위는?</a></li>
</ul>
이미지: Shutterstock
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

매주 ‘벤징가의 스톡 위스퍼 지수(Benzinga's Stock Whisper Index)'는 독점 데이터(proprietary data)와 패턴 인식의 조합을 사용하여 <a href="https://www.benzinga.com/topic/stock-whisper-index" target="_blank" rel="noreferrer noopener">표면 바로 아래에서 주목을 끌고</a> 있는 주식 5종목을 소개한다.
투자자들은 가치가 저평가된, 관심이 적은, 새로운 주식들을 항상 찾고 있다. 소매 트레이더들에게 제공되는 무수한 방법 중에서 방대한 양의 정보를 좁혀내어 새로운 정보를 찾아내는 것이 어려운 경우가 많다. 이 지수에는 이러한 주식들이 왜 중요한지, 투자자나 일반 독자가 이 주식들을 주목해야 하는 이유에 대한 편집 논평이 포함되어 있다.
9월 20일 주의 벤징가 스톡 위스퍼 지수의 개요:
배릭 골드(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GOLD#NYSE">GOLD</a>): 이 금광업체는 연방준비제도(연준)의 금리 50bp(베이시스 포인트) 인하 발표 이후 금 가격이 상승하면서 독자들의 관심이 증가했다. 이러한 관심은 베릭 골드의 CEO인 마크 브리스토우(Mark Bristow)가 이번 주 초 금 포럼 아메리카스(Gold Forum Americas)에서 연설하고 회사가 기존 자산에서 2030년 말까지 금 환산 온스의 30% 성장을 <a href="https://www.benzinga.com/news/24/09/40915786/barrick-forecasts-strong-organic-growth-by-2030-ceo-bristow-touts-undervaluation" target="_blank" rel="noopener" data-google-interstitial="false">기대한다고 말한</a> 이후에도 나왔다.
브리스토우의 발언은 현재 운영 중인 광산과 개발 중인 광산에 중점을 두었으며, 이 산업이 인수합병 활동의 급증을 경험하는 가운데 회사가 구리 포트폴리오를 확장하고 있다는 점도 강조되었습니다. 이는 투자자들이 주목할 만한 흥미로운 요소가 될 수 있다.
아래의 <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092024&amp;t=be2bearmibe3na1" target="_blank" rel="noopener">Benzinga Pro</a> 차트에서 볼 수 있듯이 배릭의 주가는 지난 5거래일 동안 2% 하락했다. 2024년 주가는 연초대비 14% 상승했다.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092024&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" class="wp-image-558808" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121633/Screenshot-183.png" sizes="(max-width: 999px) 100vw, 999px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121633/Screenshot-183.png 999w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121633/Screenshot-183-300x145.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121633/Screenshot-183-768x371.png 768w" alt="" width="999" height="483" /></a></figure>
갈메드 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLMD#NASDAQ">GLMD</a>): 이 바이오제약 회사는 신약 개발 활동이 발표된 후 일주일 동안 <a href="https://www.benzinga.com/news/24/09/40941193/galmed-pharmaceuticals-stock-is-soaring-thursday-heres-why">주가가 급등</a>했다. 갈메드(Galmed)는 심장섬유증과 대장암 및 간암을 표적으로 하는 약물 개발을 추가할 계획이다. 이 회사는 4분기에 연구 데이터를 공개할 예정이다.
갈메드의 CEO인 알렌 바하라프(Allen Baharaff)는 &#8220;갈메드가 앞으로 집중할 질환들은 전 세계 수백만 명에게 영향을 미치는 주요 공중 보건 문제로, 의료 제공자들에게는 막대한 재정적 부담을 주는 문제이다&#8221;라고 말했다.
갈메드에 대한 큰 관심으로 인해 주식은 거래 주 동안 여러 차례 매매가 중단되기도 했다. Benzinga Pro에 따르면, 약 625,000주의 주식이 유통되고 있어 이 바이오제약 회사의 변동성을 높이는 데 기여했다. 변동성이 낮은 주식은 회사 발표에서 종종 높은 변동성을 볼 수 있다.
주가는 지난 5일 동안 160% 상승했으며, 2024년 연초 이후 주가는 거의 100% 상승했다.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092024&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" class="wp-image-558810" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121656/Screenshot-184.png" sizes="(max-width: 993px) 100vw, 993px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121656/Screenshot-184.png 993w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121656/Screenshot-184-300x152.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121656/Screenshot-184-768x388.png 768w" alt="" width="993" height="502" /></a></figure>
또한 읽기: <a href="https://kr.benzinga.com/news/usa/stocks/%eb%8b%a8%eb%8f%85-2024%eb%85%84-8%ec%9b%94-%eb%b2%a4%ec%a7%95%ea%b0%80-%ed%94%84%eb%a1%9c%ec%97%90%ec%84%9c-%ea%b0%80%ec%9e%a5-%ea%b2%80%ec%83%89%eb%9f%89%ec%9d%b4-%eb%a7%8e%ec%95%98%eb%8d%98/" target="_blank" rel="noopener">독점: 8월 Benzinga Pro에서 가장 많이 검색된 20개 티커 – 테슬라, 엔비디아, 애플, AMD 주식 순위는?</a>
서비스나우(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>): 이 소프트웨어 회사는 3분기 재무 결과를 앞두고 독자들의 관심이 크게 증가하고 있다. 분석가들은 이 회사의 매출이 작년 3분기 22억 9천만 달러보다 증가한 27억 4천만 달러에 이를 것으로 예상하고 있다.
이 회사는 6분기 연속으로 분석가의 매출 추정치를 상회했다. 분석가들은 회사가 지난해 3분기 2.92달러에서 증가한 3.46달러의 주당 순이익을 보고할 것으로 예상하고 있다. 서비스나우는 20분기 이상 연속으로 분석가들의 예상 이익을 넘어섰다.
이 회사의 실적 보고서는 투자자와 애널리스트들에게 매출 성장과 AI 플랫폼 수요가 계속해서 강화되고 있는지를 보여줄 것이다. 이 회사는 구독 매출이 지난해 대비 23% 증가했다고 발표했으며 <a href="https://www.benzinga.com/news/earnings/24/07/39944577/servicenow-q2-earnings-revenue-beat-eps-beat-servicenow-intends-to-reinvent-every-workflow-in-every">2분기</a>에 CEO들이 새로운 성장 기회를 찾고 있는 수요를 충족하는 데 도움을 주고 있다고 언급했다. 서비스나우는 &#8220;모든 회사, 모든 산업의 모든 워크플로우를 GenAI를 핵심으로 재구성&#8221;하고 있다.
서비스나우의 주가는 지난 5일 동안 4% 상승했으며, 2024년 연초 이후 34% 상승했다.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092024&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" class="wp-image-558811" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121712/Screenshot-185.png" sizes="(max-width: 997px) 100vw, 997px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121712/Screenshot-185.png 997w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121712/Screenshot-185-300x155.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121712/Screenshot-185-768x396.png 768w" alt="" width="997" height="514" /></a></figure>
도이체 방크(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DB#NYSE">DB</a>): 은행 주식이 스톡 위스퍼 지수에 오르는 것이 매주는 아니지만 여기에 있다. 도이체 방크는 독자들의 높은 관심을 보았으며, 이는 <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/09/40928301/interest-rates-in-free-fall-what-it-means-for-mortgages-credit-cards-and-your-wallet-a">금리 인하 발표</a> 이후 은행 주가가 상승했기 때문일 수 있다.
이러한 움직임은 대출 기관의 재무 상태를 강화하고 대출 수요를 증가시킬 수 있다. 도이체 방크는 10월에 3분기 재무 결과를 발표하고, 수요와 회사 및 업계의 미래에 대해 언급할 수 있다.
주가는 지난 5일 동안 5% 상승했으며, 2024년 연초 이후 24% 상승했다.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092024&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" class="wp-image-558812" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121726/Screenshot-186.png" sizes="(max-width: 999px) 100vw, 999px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121726/Screenshot-186.png 999w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121726/Screenshot-186-300x151.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121726/Screenshot-186-768x387.png 768w" alt="" width="999" height="504" /></a></figure>
스트라이커(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>): 이 의료 장비 회사는 인수 발표, 신제품 및 <a href="https://www.benzinga.com/quote/SYK/analyst-ratings">애널리스트 노트</a>에 이어 이번 주 동안 독자들의 큰 관심을 받았다.
이 회사는 최근 팔다리 길이를 복원하는 데 도움이 될 수 있는 새로운 발 및 발목 솔루션을 공개했다. 스트라이커는 인공지능(AI) 지원 가상 진료 워크플로 및 스마트 룸 기술을 지원하는 회사인 비상장 care.ai 인수를 완료했다. 이 인수는 디지털 비전을 가속화하고 헬스케어 IT 사업을 확장하는 데 도움이 될 것이다.
금요일, 스트라이커는 종양 및 뇌내 출혈 수술 방법을 가진 니코(NICO Corporation)의 인수를 완료했다. 또한, 스트라이커는 8월에 통증 관리 회사인 버토스 메디컬(Vertos Medical)의 인수를 발표했다. 이러한 인수 및 신제품들은 투자자들이 회사의 미래와 잠재적 다각화 노력에 대해 흥분하게 만들 수 있다.
파이퍼 샌들러(Piper Sandler)는 주식에 대해 비중 확대 등급과 380달러의 목표 주가를 유지하였고, 울프 리서치(Wolfe Research)는 주식을 아웃퍼폼 등급과 405달러의 목표 주가로 커버리지를 시작했다.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092024&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" class="wp-image-558813" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121742/Screenshot-187.png" sizes="(max-width: 993px) 100vw, 993px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121742/Screenshot-187.png 993w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121742/Screenshot-187-300x151.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121742/Screenshot-187-768x387.png 768w" alt="" width="993" height="501" /></a></figure>
다음 주 보고서를 기대해 주세요. 그리고 Benzinga Pro를 팔로우하여 최신 헤드라인과  <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092024&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">주요 시장 변동 이야기를 확인하세요.</a>
다음 읽어볼 것:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/40838414/gold-miners-eye-best-1-day-rally-in-6-months-as-gold-hits-fresh-record-highs-todays-environment-">금 가격이 사상 최고가를 기록하면서 금광업체들이 6개월 만에 하루 최대 반등을 노리고 있다: &#8216;오늘의 환경은 1970년대와 유사하다.&#8217;</a></li>
</ul>
사진: Benzinga
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Galmed Pharmaceuticals

뉴스

에 대한 최신 뉴스 Galmed Pharmaceuticals (NASDAQ:GLMD) 주식

월요일, 11월 04, 2024

수요일, 10월 02, 2024

토요일, 9월 21, 2024

뉴스

파트너 / 기고자

벤징가 글로벌